


New

suralan®

Sarolaner

High protection in LESS DOSAGE

Low dose and fast action oral ectoparasiticide.
Controls fleas, ticks and mange mites.
Adulticide, ovide and larvicide.



**35 days of
Protection**


**Works after
90 minutes**



suralan®

A differentiated isoxazoline

Suralan® is composed of an isoxazoline, sarolaner, an ultra-purified active ingredient, which is an excellent ectoparasitic treatment with systemic action against fleas, ticks and mites.



Higher purity

The pharmacological activity of Suralan® resides in its enantiomeric form the chirally pure S-enantiomer* present in its composition. Enantiomers require less active ingredient to exert an antiparasitic effect than chiral R molecules such as Fluralaner and Afoxolaner.

High

protection in
LESS DOSAGE

suralan®
2 mg / kg

afoxolaner
2,7 mg / kg

fluralaner**
10 mg / kg


Effective against
fleas, ticks and
mange mites



Works after
90 minutes



35 days of
Protection



A soft tablet with excellent palatability

Its exclusive technology gives it a great acceptance due to its attractive smell, flavor and soft consistency.

*Ultra Purified, analyzed by means of a chiral column to specifically differentiate and quantify the active enantiomer, with the objective of guaranteeing a purity higher than 99%.

** Fluralaner in 1 month presentation.

For all sizes

Protection for extra mini size dogs from 1.5 kg to extra large 60 kg.



Security


Safe for all dog breeds from 8 weeks of age.



PROTECTION PROVEN BY FIELD STUDIES UNDER **REAL CONDITIONS**

Fleas


The onset of flea activity of Suralan® is 92 minutes on average after administration¹. At 4 hours after initiation of treatment, it has shown an effectiveness of 95%, reaching 99% at 8 hours², which is maintained until day 35.



Ticks


The administration of one tablet of Suralan® represents an effective alternative for the treatment and control of ticks, with an effectiveness of 88% in the first 8 hours³.

Suralan® maintains its efficacy persistently for more than 35 days, proving to be a reliable alternative in the treatment of ectoparasites in dogs³.



FAD

Adjuvant in the control of flea allergy dermatitis.



Safe environment

Facilitates control of environmental flea infestations in the home.



Dosage and Route of Administration

Suralan® is administered orally, according to the following table (doses correspond to 2-4 mg sarolaner/kg live weight within each weight range).

suralan®	Sarolaner mg/ Tab	Range Body Weight (kg) Min - Max	Minimum Dose (mg/kg)	Maximum Dose (mg/kg)	Tablet Weight (mg)
Suralan® X-Mini	5 mg	1.25 - 2.5	2	4	500
Suralan® Mini	10 mg	2.5 - 5	2	4	1000
Suralan® Small	20 mg	5 - 10	2	4	2000
Suralan® Medium	40 mg	10 - 20	2	4	1000
Suralan® Large	80 mg	20 - 40	2	4	2000
Suralan® X-Large	120 mg	40 - 60	2	4	3000

Available in presentation
of **1 and 4 units of soft
chewable tablets.**



Tested palatability

Suralan® has been shown in studies to have high palatability and acceptance according to the palatability score, where 84% of the dogs consumed the tablet voluntarily⁴.

Palatability score				Voluntary acceptance	Average
0	1	2	3		
15.91%	0%	9.09%	75%	84.09%	2.43

Score: 0 The animal must be forced to eat the product. 1 The animal shows interest at first but should be forced to eat the product. 2 The animal shows interest and eats the product when it is placed on the animal's snout. 3 The animal smells the product and eats it voluntarily.

BIBLIOGRAPHIC REFERENCE

1.-Flores L, Krklec S, Pilar A. 2024. Evaluation of the time of onset of fleaicidal activity of an oral formulation based on sarolaner administered monthly in canines. 2.- Flores L, Krklec S, Pilar A. 2024. Effectiveness, tolerance and residual effect of a chewable tablet based on sarolaner for the treatment and control of fleas in naturally infested canines. 3.-Flores L, Krklec S, Pilar A. 2024. Effectiveness, tolerance and residual effect of a chewable tablet based on sarolaner for the treatment and control of ticks in naturally infested canines. 4.- Flores L, Krklec S, Pilar A. 2024. Evaluation of the palatability of a sarolaner-based chewable tablet in canines.



Sample materials, packaging, whether digital or printed, provided by Agrovét Market or its representatives are intended for informational purposes only. The content is global and general in nature and shall not, under any circumstances, be construed as an attempt to undermine, infringe, or challenge the validity of any registration, patent, or intellectual property right in the country where this information is distributed or received.